Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.Across the 68 markets, sales ...
In this target trial emulation, glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a lower risk of ...
Many peptide medications like glucagon-like peptide-1 (GLP-1) receptor agonists were initially developed to treat type 2 diabetes. One unexpected side effect of these drugs is weight loss.
In response to the growing interest in glucagon-like peptide-1 (GLP-1) weight-loss medications and the cost challenges employers face to offer coverage, Liviniti, a national leader in PBM innovation, ...
Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...
Depression risk lower with GLP-1 receptor agonists versus DPP-4 inhibitors in seniors, study reveals
For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with ...
Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class ...
Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent ...
Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...
GLP-1 RAs show protective effects against primary open-angle glaucoma and ocular hypertension, surpassing alternative weight ...
Some studies link GLP-1 drugs for diabetes with neuroprotective benefits but others say that some of these drugs may increase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results